Nicholas Saraceno, Editor

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares how stakeholders can drive meaningful, lasting impact by turning pledges into proof points, exercising patience, and embedding sustainability into core business operations.

The program measures a company’s air cargo supply chain efforts when it comes to quality, safety, and compliance.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, outlines how US tariffs on Canadian goods have impacted the company’s operations, particularly in terms of cost and supply chain management in the US market.

Joydeep Ganguly, SVP, corporate operations, interim CIO, Gilead Sciences, shares insights on how sustainability has evolved from a compliance requirement to a key business strategy, driving operational efficiencies, innovation, and long-term growth.

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, outlines the implications that potential 25% tariffs on pharmaceuticals could have, as far as manufacturers reshoring their production services are concerned.

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, comments on the steps needed to achieve Drug Supply Chain Security Act compliance.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, describes his day-to-day workflow at Morris & Dickson, and how it supports the efficiency and reliability of the distributor’s operations.

Will Robinson, program director, LogiPharma, shares how in-depth conversations—not AI—drive the research behind one of the industry's most anticipated annual agendas.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jody Hatcher, CEO of Morris & Dickson and chair of HDA’s board of directors, explains how he foresees the future of the organization, along with the role he hopes to play in shaping its direction.

Will Robinson, program director, LogiPharma, explains how artificial intelligence and sustainability are driving a clear shift in priorities across the pharmaceutical supply chain.

The new firm—with 13 manufacturing facilities spanning France, Sweden, and Spain—will support the pharma supply chain through to commercialization.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, emphasizes the importance of the separation of core business and foundation, the value of patient empowerment, and the impact of digital innovation.

Will Robinson, program director, LogiPharma, reveals why the conference will be moved to Vienna moving forward.

One expert's take on reshoring pharma manufacturing services in the US amid likely tariffs to drugs looming.

Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, provides an update on where the healthcare industry currently stands in terms of compliance with price transparency regulations, and what steps need to be taken to achieve full compliance.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, discusses the biggest challenges healthcare organizations currently face in terms of price transparency.

Steffen Lang, president, operations, executive committee member, Novartis, discusses what to expect from Novartis over the next decade in terms of technological innovations.

Steffen Lang, president, operations, executive committee member, Novartis, discusses how technology will continue to enhance operations and how it will impact patients.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, comments on another presentation that has caught her eye at the conference.

Steffen Lang, president, operations, executive committee member, Novartis, shares strategic insights on how pharma supply chain leaders can elevate operations to drive innovation, growth, and patient impact.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, details the aspect of her presentation that she would have wanted to dive further into.

How can stakeholders prepare for changing therapy requirements?

A keynote presentation describes how supply chain visibility should rely on digital capabilities.

Steffen Lang, president, operations, executive committee member, Novartis, discusses the premise of a keynote session on reimagining operations.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, shares his thoughts on the rumors that RFK Jr. could potentially ban DTC advertising.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, outlines the key provisions of the recently released executive order on healthcare price transparency.